16 research outputs found
Spectral distribution of SPARC photoinjector electrons
SPARC is a photo-injector for production of high-brightness lowemittance electron beams to drive a FEL experiment in various configurations, including SASE-FEL radiation of 1β10nm (SPARCX project). Due to a high-brightness source, the SPARC facility can be used to study the physics of ultrashort beams, plasma-wave based acceleration, production of X-rays by means of Compton backscattering, channeling of electron beams and other experiments. The initial process of electron beam generation inside the RF gun determines the main parameters of the electron beam. Interaction of electrons with high-frequency laser beam
leads to modulation of the electron beam. In this paper we present electron beam spectral distribution for SPARC photoinjector parameters. The estimate of electron beam energy loss for such electron distribution also is given
ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΡΠ΅Π½ΠΎΡΠΈΠΏΠ° ΠΈΠΌΠΌΡΠ½Π½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΠΎΠΉ ΡΡΡΠΎΠΌΡ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
Introduction. Prostate cancer is by far the most frequently diagnosed cancer among the male population and ranks fifth in the world in terms of mortality rates among malignant neoplasms. Today it is known that the tumor microenvironment plays an important role in the pathogenesis of the disease. Abundant data has accumulated indicating that cells of the inflammatory infiltrate of the tumor are involved in the onset, progression and response to treatment in cases of prostate cancer. However, their role in the context of disease progression has not yet been determined. In this work, we studied the phenotype of inflammatory infiltrate of prostate cancer and its association with the clinical and morphological characteristics of patients.The study objective is to determine the features of the inflammatory infiltrate of prostate cancer and its association with the clinical and morphological characteristics of patients with this disease.Materials and methods. The study included tumor samples obtained from 31 patients with prostate cancer. The expression of CD3, CD8, FoxP3, CD68, PU.1, CD204, CD163, IDO1, PD-L1 (programmed death-ligand 1) was assessed by immunohistochemistry. The relationship between markers and clinical and morphological characteristics was assessed using the nonparametric MannβWhitney test and Fisherβs exact test. Spearmanβs rank correlation coefficient was used to analyze the correlations between contents of cells of different phenotypes. Differences were considered statistically significant at p <0.05.Results. This study describes the features of the stroma of prostate cancer. We have shown that an increased content of CD204+ cells is associated with an older age of patients (p = 0.0026), and the number of CD163+ and CD8+ cells with no metastases to regional lymph nodes (p = 0.0067 and p = 0.0069, respectively). It has been shown that PU.1 can be used as a general marker of macrophages. We also found significant correlations between the level of PU.1 and PD-L1 in the stroma (r = 0.421; p = 0.018) and IDO1 in the stroma (r = 0.557; p = 0.001) and in tumor cells (r = 0.393; p = 0.029), CD68 with IDO1 in the stroma (r = 0.535; p = 0.002), CD163 with PD-L1 and IDO1 in the stroma (r = 0.399; p = 0.026 and r = 0.220; p = 0.026, respectively).Conclusion. In this work, the characteristics of the stroma of prostate cancer were investigated. Our data indicate that tumor associated macrophages are the main cells expressing PD-L1 and IDO1 in the tumor stroma in the case of prostate cancer. Increased expression of IDO1 in tumor tissue is associated with the immunosuppressive phenotype of the inflammatory infiltrate. The fact that the number of macrophages directly correlates with the number of T-lymphocytes in the prostate stroma, and the number of M2 macrophages with cytotoxic T-cells indicates the interaction of the mechanisms of innate and acquired immunity during the progression of prostate cancer.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π Π°ΠΊ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Π½Π° ΡΠ΅Π³ΠΎΠ΄Π½ΡΡΠ½ΠΈΠΉ Π΄Π΅Π½Ρ ΡΠ²Π»ΡΠ΅ΡΡΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠΎ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΡΠ΅ΠΌΡΠΌ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ΠΌ ΡΡΠ΅Π΄ΠΈ ΠΌΡΠΆΡΠΊΠΎΠ³ΠΎ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ ΠΈ Π·Π°Π½ΠΈΠΌΠ°Π΅Ρ 5-Π΅ ΠΌΠ΅ΡΡΠΎ Π² ΠΌΠΈΡΠ΅ ΠΏΠΎ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ ΡΡΠ΅Π΄ΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ. ΠΠ·Π²Π΅ΡΡΠ½ΠΎ, ΡΡΠΎ ΠΌΠΈΠΊΡΠΎΠΎΠΊΡΡΠΆΠ΅Π½ΠΈΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΈΠ³ΡΠ°Π΅Ρ Π±ΠΎΠ»ΡΡΡΡ ΡΠΎΠ»Ρ Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. ΠΠ°ΠΊΠΎΠΏΠ»Π΅Π½ΠΎ ΠΌΠ½ΠΎΠ³ΠΎ Π΄Π°Π½Π½ΡΡ
, ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡΠΈΡ
ΠΎ ΡΠΎΠΌ, ΡΡΠΎ ΠΊΠ»Π΅ΡΠΊΠΈ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠ° ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΡΡΠ°ΡΡΠ²ΡΡΡ Π² Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΠΈ, ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΠΈ ΠΈ ΠΎΡΠ²Π΅ΡΠ΅ Π½Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π² ΡΠ»ΡΡΠ°ΡΡ
ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΠ΄Π½Π°ΠΊΠΎ ΠΈΡ
ΡΠΎΠ»Ρ Π² ΠΊΠΎΠ½ΡΠ΅ΠΊΡΡΠ΅ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π΅ΡΠ΅ Π½Π΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π°. Π² ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅Π½ΠΎΡΠΈΠΏΠ° Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠ° ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΠΈ Π΅Π³ΠΎ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΠΈ Ρ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ².Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠ° ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΠΈ Π΅Π³ΠΎ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΠΈ Ρ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π΄Π°Π½Π½ΡΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ΠΌ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΡΠ»ΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ ΠΎΠ±ΡΠ°Π·ΡΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΠΎΡ 31 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. Π‘ ΠΏΠΎΠΌΠΎΡΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ CD3, CD8, FoxP3, CD68, PU.1, CD204, CD163, IDO1 ΠΈ PD-L1 (Π»ΠΈΠ³Π°Π½Π΄Π° ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΠΈΡΡΠ΅ΠΌΠΎΠΉ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ Π³ΠΈΠ±Π΅Π»ΠΈ 1). ΠΠ»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·ΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈΡΡ Π½Π΅ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΠΌΠ°Π½Π½Π°βΠ£ΠΈΡΠ½ΠΈ ΠΈ ΡΠΎΡΠ½ΡΠΉ ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΡΠΈΡΠ΅ΡΠ°. ΠΠ»Ρ Π°Π½Π°Π»ΠΈΠ·Π° ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΉ ΠΌΠ΅ΠΆΠ΄Ρ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ΠΌ ΠΊΠ»Π΅ΡΠΎΠΊ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΠ΅Π½ΠΎΡΠΈΠΏΠΎΠ² ΠΏΡΠΈΠΌΠ΅Π½ΡΠ»ΠΈ ΠΊΠΎΡΡΡΠΈΡΠΈΠ΅Π½Ρ ΡΠ°Π½Π³ΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ ΡΠΏΠΈΡΠΌΠ΅Π½Π°. Π²ΠΎ Π²ΡΠ΅Ρ
Π°Π½Π°Π»ΠΈΠ·Π°Ρ
Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ p β€0,05 ΡΡΠΈΡΠ°Π»ΠΎΡΡ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΠΌ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π Ρ
ΠΎΠ΄Π΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Ρ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΡΡΠΎΠΌΡ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΡΠ»ΠΎ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ, ΡΡΠΎ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΠΎΠ΅ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ CD204+-ΠΊΠ»Π΅ΡΠΎΠΊ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½ΠΎ Ρ Π±ΠΎΠ»Π΅Π΅ ΡΡΠ°ΡΡΠΈΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠΎΠΌ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (Ρ = 0,0026), Π° ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ CD163+- ΠΈ CD8+-ΠΊΠ»Π΅ΡΠΎΠΊ β Ρ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΎΠ² Π² ΡΠ΅Π³ΠΈΠΎΠ½Π°ΡΠ½ΡΠ΅ Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ·Π»Ρ (Ρ = 0,0067 ΠΈ Ρ = 0,0069 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ PU.1 ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ ΠΊΠ°ΠΊ ΠΎΠ±ΡΠΈΠΉ ΠΌΠ°ΡΠΊΠ΅Ρ ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ². Π’Π°ΠΊΠΆΠ΅ ΠΌΡ Π²ΡΡΠ²ΠΈΠ»ΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠ΅ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ ΡΡΠΎΠ²Π½Ρ PU.1 Ρ PD-L1 Π² ΡΡΡΠΎΠΌΠ΅ (r = 0,421; Ρ = 0,018), IDO1 Π² ΡΡΡΠΎΠΌΠ΅ (r = 0,557; p = 0,001) ΠΈ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΊΠ»Π΅ΡΠΊΠ°Ρ
(r = 0,393; Ρ = 0,029), Π° ΡΠ°ΠΊΠΆΠ΅ CD68 c IDO1 (r = 0,535; p = 0,002) ΠΈ ΡD163 c PDL1 ΠΈ IDO1 Π² ΡΡΡΠΎΠΌΠ΅ (r = 0,399; p = 0,026 ΠΈ r = 0,220; p = 0,026 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠ»ΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈ ΡΡΡΠΎΠΌΡ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΡΠΊΠ°Π·ΡΠ²Π°ΡΡ Π½Π° ΡΠΎ, ΡΡΠΎ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌΠΈ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ, ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡΡΡΡΠΈΠΌΠΈ PD-L1 ΠΈ IDO1 Π² ΡΡΡΠΎΠΌΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ, Π² ΡΠ»ΡΡΠ°Π΅ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΡΠ²Π»ΡΡΡΡΡ ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΈ, ΠΈΠ½ΡΠΈΠ»ΡΡΡΠΈΡΡΡΡΠΈΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»Ρ. ΠΠΎΠ²ΡΡΠ΅Π½Π½Π°Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ IDO1 Π² ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π° Ρ ΠΈΠΌΠΌΡΠ½ΠΎΡΡΠΏΡΠ΅ΡΡΠΎΡΠ½ΡΠΌ ΡΠ΅Π½ΠΎΡΠΈΠΏΠΎΠΌ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠ°. ΡΠΎΡ ΡΠ°ΠΊΡ, ΡΡΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² ΠΏΡΡΠΌΠΎ ΠΊΠΎΡΡΠ΅Π»ΠΈΡΡΠ΅Ρ Ρ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎΠΌ Ρ-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π² ΡΡΡΠΎΠΌΠ΅ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, Π° ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² 2-Π³ΠΎ ΡΠΈΠΏΠ° β Ρ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Ρ-ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ, ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ ΠΎ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠΈ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΎΠ² Π²ΡΠΎΠΆΠ΄Π΅Π½Π½ΠΎΠ³ΠΎ ΠΈ ΠΏΡΠΈΠΎΠ±ΡΠ΅ΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ° Π² ΠΏΡΠΎΡΠ΅ΡΡΠ΅ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΠΈ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ
ΠΠΌΠΌΡΠ½ΠΎΡΡΠΏΡΠ΅ΡΡΠΎΡΠ½ΡΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΠ΅Π½ΠΎΡΠΈΠΏΠ° ΡΡΡΠΎΠΌΡ ΠΎΠΏΡΡ ΠΎΠ»Π΅ΠΉ ΠΏΠΎΡΠΊΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠΈΠΏΠΎΠ²
Background. Renal cell carcinoma is a heterogeneous group of tumors characterized by high vascularization and immunogenicity. Immunotherapy has made a breakthrough in the treatment of this pathology, however, the lack of development of criteria for its use does not allow to achieve even greater success. It is known that the tumor stroma plays an important role in the success of immunotherapy. Among the various histological types of kidney tumors, the stroma of the clear cell renal cell carcinoma has been studied in sufficient detail. However, the remaining histological types are practically not studied.Objective: description of the immunosuppressive phenotype of the stroma of kidney tumors of various histological types.Materials and methods. The study included tumor samples obtainedfrom 44patients with renal cell carcinoma of various histological types (16 samples of chromophobe cancer, 15 samples of clear cell and 13 samples of papillary renal cell carcinoma). The method of immunohis-tochemistry evaluated the expression of tumor stromal markers, namely CD68, CD206, PU.1, CD3, IDO1 and PD-L1 in the studied samples.Results. Analysis of the total number of macrophages associated with the tumor showed that the smallest number is observed in samples of chromophobe renal cancer, while in the samples of clear cell cancer their number is greatest. A similar situation is observed for T-cells: the largest number of CD3+ cells is observed in clear cell tumors. In chromophobe and papillary tumors, their number is reduced. Papillary tumors are also characterized by an almost complete absence of expression of PD-L1 and IDO1 compared to other histological types of kidney tumors. We also showed that for PU.1 there is a strong positive correlation between its quantity and localization, as in CD68. Thus, PU.1 can be used as a general marker for describing stromal macrophages in kidney tumors.Conclusion. The study showed that kidney tumors of various histological types strongly and significantly differ in the composition of their microenvironment. These data, of course, must be considered when choosing immune therapy in the treatment of this pathology.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠΎΡΠ΅ΡΠ½ΠΎ-ΠΊΠ»Π΅ΡΠΎΡΠ½Π°Ρ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠ° ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΡΠΎΠ±ΠΎΠΉ Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΡΡ Π³ΡΡΠΏΠΏΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΡΡΡΡ Π²ΡΡΠΎΠΊΠΎΠΉ Π²Π°ΡΠΊΡΠ»ΡΡΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΡΡΡΡ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ³Π΅Π½Π½ΠΎΡΡΡΡ. ΠΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΡΠΎΠ²Π΅ΡΡΠΈΠ»Π° ΠΏΡΠΎΡΡΠ² Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π΄Π°Π½Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ, ΠΎΠ΄Π½Π°ΠΊΠΎ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ Π²ΡΡΠ°Π±ΠΎΡΠΊΠΈ ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π² Π΅Π΅ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π½Π΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π΄ΠΎΠ±ΠΈΡΡΡΡ Π΅ΡΠ΅ Π±ΠΎΠ»ΡΡΠΈΡ
ΡΡΠΏΠ΅Ρ
ΠΎΠ². ΠΠ·Π²Π΅ΡΡΠ½ΠΎ, ΡΡΠΎ Π² ΡΡΠΏΠ΅Ρ
Π΅ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π½Π΅ΠΌΠ°Π»ΠΎΠ²Π°ΠΆΠ½ΡΡ ΡΠΎΠ»Ρ ΠΈΠ³ΡΠ°Π΅Ρ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²Π°Ρ ΡΡΡΠΎΠΌΠ°. Π‘ΡΠ΅Π΄ΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΏΠΎΠ² ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΠΏΠΎΡΠΊΠΈ ΡΡΡΠΎΠΌΠ° ΡΠ²Π΅ΡΠ»ΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ Π²Π°ΡΠΈΠ°Π½ΡΠ° ΠΏΠΎΡΠ΅ΡΠ½ΠΎ-ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ ΠΈΠ·ΡΡΠ΅Π½Π° Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΠΏΠΎΠ΄ΡΠΎΠ±Π½ΠΎ. ΠΠ΄Π½Π°ΠΊΠΎ ΠΎΡΡΠ°Π»ΡΠ½ΡΠ΅ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠΈΠΏΡ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅ ΠΈΠ·ΡΡΠ΅Π½Ρ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΠΏΠΈΡΠ°Π½ΠΈΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎΡΡΠΏΡΠ΅ΡΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠ΅Π½ΠΎΡΠΈΠΏΠ° ΡΡΡΠΎΠΌΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΠΏΠΎΡΠΊΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΏΠΎΠ². ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΡΠ»ΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ ΠΎΠ±ΡΠ°Π·ΡΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΠΎΡ 44 Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΠΎΡΠ΅ΡΠ½ΠΎ-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΏΠΎΠ² (16 ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² Ρ
ΡΠΎΠΌΠΎΡΠΎΠ±Π½ΠΎΠ³ΠΎ, 15 ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΡΠ²Π΅ΡΠ»ΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΈ 13 ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΠΏΠ°ΠΏΠΈΠ»Π»ΡΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΠΏΠΎΡΠΊΠΈ). Π ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
ΠΎΠ±ΡΠ°Π·ΡΠ°Ρ
ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΎΡΠ΅Π½ΠΊΠ° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ ΡΡΡΠΎΠΌΡ, Π° ΠΈΠΌΠ΅Π½Π½ΠΎ CD68, CD206, PU.1, CD3, IDO1 ΠΈ PD-L1.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ½Π°Π»ΠΈΠ· ΠΎΠ±ΡΠ΅Π³ΠΎ ΡΠΈΡΠ»Π° ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ², Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Ρ ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ, ΠΏΠΎΠΊΠ°Π·Π°Π», ΡΡΠΎ Π½Π°ΠΈΠΌΠ΅Π½ΡΡΠ΅Π΅ ΠΈΡ
ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ Π½Π°Π±Π»ΡΠ΄Π°Π΅ΡΡΡ Π² ΠΎΠ±ΡΠ°Π·ΡΠ°Ρ
Ρ
ΡΠΎΠΌΠΎΡΠΎΠ±Π½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΠΏΠΎΡΠΊΠΈ, Π² ΡΠΎ Π²ΡΠ΅ΠΌΡ ΠΊΠ°ΠΊ Π² ΠΎΠ±ΡΠ°Π·ΡΠ°Ρ
ΡΠ²Π΅ΡΠ»ΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΠΈΡ
ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅Π΅. ΠΠ»Ρ Π’-ΠΊΠ»Π΅ΡΠΎΠΊ ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° ΠΏΠΎΡ
ΠΎΠΆΠ°Ρ ΡΠΈΡΡΠ°ΡΠΈΡ: Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅Π΅ ΡΠΈΡΠ»ΠΎ CD3+-ΠΊΠ»Π΅ΡΠΎΠΊ Π½Π°Π±Π»ΡΠ΄Π°Π΅ΡΡΡ Π² ΡΠ²Π΅ΡΠ»ΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ
. Π Ρ
ΡΠΎΠΌΠΎΡΠΎΠ±Π½ΡΡ
ΠΈ ΠΏΠ°ΠΏΠΈΠ»Π»ΡΡΠ½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ
ΠΈΡ
ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΎ. Π’Π°ΠΊΠΆΠ΅ ΠΏΠ°ΠΏΠΈΠ»Π»ΡΡΠ½ΡΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΡΡ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ ΠΏΠΎΠ»Π½ΡΠΌ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ PD-L1 ΠΈ IDO1 ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π΄ΡΡΠ³ΠΈΠΌΠΈ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΡΠΈΠΏΠ°ΠΌΠΈ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΠΏΠΎΡΠΊΠΈ. Π’Π°ΠΊΠΆΠ΅ ΠΌΡ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ, ΡΡΠΎ Π΄Π»Ρ PU.1 Π½Π°Π±Π»ΡΠ΄Π°Π΅ΡΡΡ ΡΠΈΠ»ΡΠ½Π°Ρ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΡ Π΅Π³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° Ρ Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΠ΅ΠΉ, ΠΊΠ°ΠΊ ΠΈ Π΄Π»Ρ CD68. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, PU.1 ΠΌΠΎΠΆΠ½ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΎΠ±ΡΠ΅Π³ΠΎ ΠΌΠ°ΡΠΊΠ΅ΡΠ° Π΄Π»Ρ ΠΎΠΏΠΈΡΠ°Π½ΠΈΡ ΡΡΡΠΎΠΌΠ°Π»ΡΠ½ΡΡ
ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² Π² ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ
ΠΏΠΎΡΠΊΠΈ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ, ΡΡΠΎ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΏΠΎΡΠΊΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΏΠΎΠ² ΡΠΈΠ»ΡΠ½ΠΎ ΠΈ Π·Π½Π°ΡΠΈΠΌΠΎ ΠΎΡΠ»ΠΈΡΠ°ΡΡΡΡ ΠΏΠΎ ΡΠΎΡΡΠ°Π²Ρ ΡΠ²ΠΎΠ΅Π³ΠΎ ΠΌΠΈΠΊΡΠΎΠΎΠΊΡΡΠΆΠ΅Π½ΠΈΡ. ΠΡΠΎ, Π½Π΅ΡΠΎΠΌΠ½Π΅Π½Π½ΠΎ, Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ ΡΡΠΈΡΡΠ²Π°ΡΡ ΠΏΡΠΈ Π²ΡΠ±ΠΎΡΠ΅ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π΄Π°Π½Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ
ΠΠ΅Π»ΠΊΠΈ sPD-1/sPD-L1 ΠΏΡΠΈ Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΌ ΡΠ°ΠΊΠ΅ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΈ ΠΏΠ»ΠΎΡΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΌ ΡΠ°ΠΊΠ΅ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π°
Background. Implementation of immunotherapy in clinical oncological practice has significantly improved the results of cancer treatment. It resulted in the need for seeking new markers to assess the effectiveness of therapy and the disease prognosis.Aim. To analyze the content of soluble forms of PD-1 and PD-L1 immune checkpoint proteins in the blood serum of patients with non-small cell lung cancer and esophageal squamous cell carcinoma and their association with clinical and morphological characteristics of the disease and the disease prognosis.Materials and methods. The study included tumor samples obtained from 43 patients with non-small cell lung cancer and 21 patients with esophageal squamous cell carcinoma. The concentration of sPD-L1 and sPD-1 in the blood serum was determined using enzyme-linked immunosorbent assay (ELISA). The Mann β Whitney test was used to determine statistically significant differences in independent groups. A correlation analysis was performed using the Spearmanβs rank correlation coefficient. Overall survival was analyzed by constructing survival curves using the Kaplan β Meier method and a Cox proportional hazards model. The differences were considered statistically significant at p < 0.05.Results. The study showed that sPD-1 and sPD-L1 were found in the blood serum of both cancer patients and healthy donors, and their concentrations did not differ significantly. It was shown that the high concentration of sPD-L1 in the blood serum of patients with non-small cell lung cancer was significantly associated with the late stage of the disease and was an independent unfavorable prognostic factor. It should be noted that for patients with esophageal cancer, an unfavorable prognostic marker was the high concentration of the soluble form of PD-1 protein, and not PD-L1 ligand, as in case of lung cancer.Conclusion. The content of sPD-1 and sPD-L1 in the blood serum can have different prognostic significance for various types of cancer, and further studies are required to confirm their clinical usability.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠΊΡΠΈΠ²Π½ΠΎΠ΅ Π²Π½Π΅Π΄ΡΠ΅Π½ΠΈΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΡΡ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΡΡ ΠΏΡΠ°ΠΊΡΠΈΠΊΡ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΎ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠ»ΡΡΡΠΈΡΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ. ΠΡΠΎ ΠΏΡΠΈΠ²Π΅Π»ΠΎ ΠΊ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΠΈ ΠΏΠΎΠΈΡΠΊΠ° Π½ΠΎΠ²ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ², Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΊΠΎΡΠΎΡΡΡ
ΠΌΠΎΠΆΠ½ΠΎ ΠΎΡΠ΅Π½ΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠΌΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ· Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β Π°Π½Π°Π»ΠΈΠ· ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΡΡ
ΡΠΎΡΠΌ Π±Π΅Π»ΠΊΠΎΠ² ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΡΠΎΡΠ΅ΠΊ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ° sPD-1 ΠΈ PD-L1 Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΈ ΠΏΠ»ΠΎΡΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π°, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΈΡ
Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΠΈ Ρ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΎΠΌ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ ΠΎΠ±ΡΠ°Π·ΡΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΠΎΡ 43 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΈ 21 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ ΠΏΠ»ΠΎΡΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π°. ΠΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ sPD-L1 ΠΈ sPD-1 ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°. ΠΠ»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ
ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π² Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΡΡ
Π³ΡΡΠΏΠΏΠ°Ρ
ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΠΠ°Π½Π½Π° β Π£ΠΈΡΠ½ΠΈ. ΠΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΊΠΎΡΡΡΠΈΡΠΈΠ΅Π½ΡΠ° ΡΠ°Π½Π³ΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ Π‘ΠΏΠΈΡΠΌΠ΅Π½Π°. ΠΠ½Π°Π»ΠΈΠ· ΠΎΠ±ΡΠ΅ΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ β ΠΏΡΡΠ΅ΠΌ ΠΏΠΎΡΡΡΠΎΠ΅Π½ΠΈΡ ΠΊΡΠΈΠ²ΡΡ
Π΄ΠΎΠΆΠΈΡΠΈΡ ΠΏΠΎ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΠ°ΠΏΠ»Π°Π½Π° β ΠΠ΅ΠΉΠ΅ΡΠ° ΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΌΠΎΠ΄Π΅Π»ΠΈ ΠΏΡΠΎΠΏΠΎΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠΈΡΠΊΠΎΠ² ΠΠΎΠΊΡΠ°. Π‘ΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠΌΠΈ ΡΡΠΈΡΠ°Π»ΠΈΡΡ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΠΏΡΠΈ Ρ < 0,05.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ sPD-1ΠΈ sPD-L1 ΠΎΠ±Π½Π°ΡΡΠΆΠΈΠ²Π°ΡΡΡΡ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΊΠ°ΠΊ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ, ΡΠ°ΠΊ ΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄ΠΎΠ½ΠΎΡΠΎΠ², ΠΈ ΠΈΡ
ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π·Π½Π°ΡΠΈΠΌΠΎ Π½Π΅ ΠΎΡΠ»ΠΈΡΠ°ΡΡΡΡ. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π²ΡΡΠΎΠΊΠ°Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ sPD-L1 Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π° Ρ ΠΏΠΎΠ·Π΄Π½Π΅ΠΉ ΡΡΠ°Π΄ΠΈΠ΅ΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΡΠΌ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ. ΠΠ΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ ΠΎΡΠΌΠ΅ΡΠΈΡΡ, ΡΡΠΎ Π΄Π»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ°ΠΊΠΎΠΌ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π° Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠΌ ΡΠ²Π»ΡΠ΅ΡΡΡ Π²ΡΡΠΎΠΊΠΎΠ΅ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΠΉ ΡΠΎΡΠΌΡ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° PD-1, Π° Π½Π΅ Π΅Π³ΠΎ Π»ΠΈΠ³Π°Π½Π΄Π° PD-L1, ΠΊΠ°ΠΊ Π΄Π»Ρ ΡΠ°ΠΊΠ° Π»Π΅Π³ΠΊΠΎΠ³ΠΎ.ΠΡΠ²ΠΎΠ΄Ρ. Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ sPD-1ΠΈ sPD-L1 ΠΌΠΎΠΆΠ΅Ρ ΠΈΠΌΠ΅ΡΡ ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠ΅ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π΄Π»Ρ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π½ΠΎΠ·ΠΎΠ»ΠΎΠ³ΠΈΠΉ, ΠΈ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ Π΅Π³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Π΄Π»Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΡΠ΅Π±ΡΠ΅Ρ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅Π³ΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ
TECHNOLOGICAL SYSTEM AND A PARISH COMMUNITY
The article considers the issue of how the Orthodox community as the most traditional social community adapts to the contemporary system of technologies. First, the author describes the phenomenon of technological system, identifies its main features, capabilities and limitations. Among the key features of the technological system, the article focuses on decentralization, weakening hierarchy and strengthening horizontal links, flexibility, self-regulation, adaptability, totality and the use of man as an algorithmically acting subject. The author emphasizes that the system approach in sociology plays an important role in the study of technological systems, and N. Luhmannβs approach is relevant for the study of parish communities, though the author mentions the limitations and critique of his works. The article examines contemporary church discourse about modernization of parish communities, which is also determined by the popularization of the views of Luhmann and other representatives of the system approach. The author also focuses on the most important question of the contemporary world under the technological development, which is the future of the mankind, and the article mentions concepts βcyborgβ, βmutantβ, βcloneβ, βvirtual personβ, and βposthumanβ. The author makes a number of conclusions about how the parish community will react to the changes of the mankind, and what the most possible risks for the parish communities are considering such changes. Thus, the transformation of the parish community into a well-managed and well-functioning system or network means its rationalization, which at first seems necessary and solving urgent problems, but then one can see that it deprives the community of its vitality: a man finds himself in the community, but it does not seem to be Christian any more
Value orientations of the student youth in religious and secular universities
The article presents the results of the factor analysis applied to the data of mass survey on the value orientations of the students of secular and religious universities - Moscow Orthodox Theological Academy and Seminary, Lomonosov Moscow State University and Saint Petersburg State University. First, the authors provide a brief overview of the current state of sociological studies of values and value orientations of the youth and Russians with an emphasis on cross-cultural and other comparative contexts, which are so popular today. The article also considers different emphases in the sociological interpretation of the concepts of values and value orientations on the theoretical and empirical levels including the historical perspective. Since the research project consisted of several stages so as to solve a number of tasks and used different formats of the questionnaire for different samples (administration, professors and students), the article presents only a small part of the project designed to reveal the value orientations of students of secular and religious universities with the help of S. Schwartz and B. Bilski technique. The authors used this technique to identify similarities and differences in values and motives of students of secular and religious universities; suggest four factorial types of motivation; offer an interpretation of the observed factors and their manifestations in different student subsamples, such as the different circumstances of life of students in secular and religious universities and the more βexpertβ status of the latter in the (Christian, Orthodox) moral discourse, unlike the majority of students of secular universities, who can hardly be considered experts in secular ethics
CHID1 Is a Novel Prognostic Marker of Non-Small Cell Lung Cancer
There is an urgent need for identification of new prognostic markers and therapeutic targets for non-small cell lung cancer (NSCLC). In this study, we evaluated immune cells markers in 100 NSCLC specimens. Immunohistochemical analysis revealed no prognostic value for the markers studied, except CD163 and CD206. At the same time, macrophage markers iNOS and CHID1 were found to be expressed in tumor cells and associated with prognosis. We showed that high iNOS expression is a marker of favorable prognosis for squamous cell lung carcinoma (SCC), and NSCLC in general. Similarly, high CHID1 expression is a marker of good prognosis in adenocarcinoma and in NSCLC in general. Analysis of prognostic significance of a high CHID1/iNOS expression combination showed favorable prognosis with 20 months overall survival of patients from the low CHID1/iNOS expression group. For the first time, we demonstrated that CHID1 can be expressed by NSCLC cells and its high expression is a marker of good prognosis for adenocarcinoma and NSCLC in general. At the same time, high expression of iNOS in tumor cells is a marker of good prognosis in SCC. When used in combination, CHID1 and iNOS show a very good prognostic capacity for NSCLC. We suggest that in the case of lung cancer, tumor-associated macrophages are likely ineffective as a therapeutic target. At the same time, macrophage markers expressed by tumor cells may be considered as targets for anti-tumor therapy or, as in the case of CHID1, as potential anti-tumor agents
Immunosuppressive peculiarities of stromal cells of various kidney tumor types
Background. Renal cell carcinoma is a heterogeneous group of tumors characterized by high vascularization and immunogenicity. Immunotherapy has made a breakthrough in the treatment of this pathology, however, the lack of development of criteria for its use does not allow to achieve even greater success. It is known that the tumor stroma plays an important role in the success of immunotherapy. Among the various histological types of kidney tumors, the stroma of the clear cell renal cell carcinoma has been studied in sufficient detail. However, the remaining histological types are practically not studied.Objective: description of the immunosuppressive phenotype of the stroma of kidney tumors of various histological types.Materials and methods. The study included tumor samples obtainedfrom 44patients with renal cell carcinoma of various histological types (16 samples of chromophobe cancer, 15 samples of clear cell and 13 samples of papillary renal cell carcinoma). The method of immunohis-tochemistry evaluated the expression of tumor stromal markers, namely CD68, CD206, PU.1, CD3, IDO1 and PD-L1 in the studied samples.Results. Analysis of the total number of macrophages associated with the tumor showed that the smallest number is observed in samples of chromophobe renal cancer, while in the samples of clear cell cancer their number is greatest. A similar situation is observed for T-cells: the largest number of CD3+ cells is observed in clear cell tumors. In chromophobe and papillary tumors, their number is reduced. Papillary tumors are also characterized by an almost complete absence of expression of PD-L1 and IDO1 compared to other histological types of kidney tumors. We also showed that for PU.1 there is a strong positive correlation between its quantity and localization, as in CD68. Thus, PU.1 can be used as a general marker for describing stromal macrophages in kidney tumors.Conclusion. The study showed that kidney tumors of various histological types strongly and significantly differ in the composition of their microenvironment. These data, of course, must be considered when choosing immune therapy in the treatment of this pathology
Gd3+-Doped Magnetic Nanoparticles for Biomedical Applications
Magnetic nanoparticles (MNPs) made of iron oxides with cubic symmetry (Fe3O4, Ξ³-Fe2O3) are demanded objects for multipurpose in biomedical applications as contrast agents for magnetic resonance imaging, magnetically driven carriers for drug delivery, and heaters in hyperthermia cancer treatment. An optimum balance between the right particle size and good magnetic response can be reached by a selection of a synthesis method and by doping with rare earth elements. Here, we present a microwave-assisted polyol synthesis of iron oxide MNPs with actual gadolinium (III) doping from 0.5 to 5.1βmol.%. The resulting MNPs have an average size of 14βnm with narrow size distribution. Their surface was covered by a glycol layer, which prevents aggregation and improves biocompatibility. The magnetic hyperthermia test was performed on 1 and 2βmg/ml aqueous colloidal solutions of MNPs and demonstrated their ability to rise the temperature by 3Β°C during a 20β30βmin run. Therefore, the obtained Gd3+ MNPs are the promising material for biomedicine